Open Access

An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models

  • Authors:
    • Tomohiro Tanaka
    • Tomokazu Ohishi
    • Teizo Asano
    • Junko Takei
    • Ren Nanamiya
    • Hideki Hosono
    • Masato Sano
    • Hiroyuki Harada
    • Manabu Kawada
    • Mika K. Kaneko
    • Yukinari Kato
  • View Affiliations

  • Published online on: May 19, 2021     https://doi.org/10.3892/or.2021.8083
  • Article Number: 132
  • Copyright : © Tanaka et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Trophoblast cell surface antigen 2 (TROP2), reported to be overexpressed in several types of cancer, is involved in cell proliferation, invasion, metastasis, and poor prognosis of many types of cancer. Previously, a highly sensitive anti‑TROP2 monoclonal antibody (clone TrMab‑6; mouse IgG2b, κ) was developed using a Cell‑Based Immunization and Screening (CBIS) method. TrMab‑6 was useful for investigations using flow cytometry, western blot, and immunohistochemistry. The aim of the present study was to investigate whether TrMab‑6 possesses in vitro antibody‑dependent cellular cytotoxicity (ADCC) or complement‑dependent cytotoxicity (CDC) activities or in vivo antitumor activities using mouse xenograft models of TROP2‑overexpressed CHO‑K1 (CHO/TROP2) and breast cancer cell lines, including MCF7, MDA‑MB‑231, and MDA‑MB‑468. In vitro experiments revealed that TrMab‑6 strongly induced ADCC and CDC activities against CHO/TROP2 and the three breast cancer cell lines, whereas it did not show those activities against parental CHO‑K1 and MCF7/TROP2‑knockout cells. Furthermore, in vivo experiments on CHO/TROP2 and MCF7 xenografts revealed that TrMab‑6 significantly reduced tumor growth, whereas it did not show antitumor activities against parental CHO‑K1 and MCF7/TROP2‑knockout xenografts. The findings suggest that TrMab‑6 is a promising treatment option for TROP2‑expressing breast cancers.
View Figures
View References

Related Articles

Journal Cover

July-2021
Volume 46 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

The Cancer Story
Copy and paste a formatted citation
x
Spandidos Publications style
Tanaka T, Ohishi T, Asano T, Takei J, Nanamiya R, Hosono H, Sano M, Harada H, Kawada M, Kaneko MK, Kaneko MK, et al: An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models. Oncol Rep 46: 132, 2021
APA
Tanaka, T., Ohishi, T., Asano, T., Takei, J., Nanamiya, R., Hosono, H. ... Kato, Y. (2021). An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models. Oncology Reports, 46, 132. https://doi.org/10.3892/or.2021.8083
MLA
Tanaka, T., Ohishi, T., Asano, T., Takei, J., Nanamiya, R., Hosono, H., Sano, M., Harada, H., Kawada, M., Kaneko, M. K., Kato, Y."An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models". Oncology Reports 46.1 (2021): 132.
Chicago
Tanaka, T., Ohishi, T., Asano, T., Takei, J., Nanamiya, R., Hosono, H., Sano, M., Harada, H., Kawada, M., Kaneko, M. K., Kato, Y."An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models". Oncology Reports 46, no. 1 (2021): 132. https://doi.org/10.3892/or.2021.8083